Document is current
Any future updates will be listed below
-
Authors
Kaufmann, Horacio
Palma, Jose-Alberto
Vickery, Ross
Norcliffe-Kaufmann, Lucy
Zheng, Beiyao
Lewin, David
Guerin, Tadhg
-
Funding
Funding for this research was provided by:
Theravance Biopharma
- License Information
-
More Information
Article History
Received: 6 August 2025
Accepted: 5 October 2025
First Online: 24 October 2025
Declarations
:
: H. Kaufmann is Editor-in-Chief of Clinical Autonomic Research , published by Springer-Nature, and serves as PI of studies sponsored by Biogen MA Inc. (TRACK MSA, S19-01846) and Vaxxinity Inc. (UB-312, S22-01332). He has received consultant fees from Takeda Pharmaceutical Company Ltd, Ono Pharma UK Ltd, Theravance Biopharma US LLC., and Parexel. He receives royalties from UpToDate. He receives research support from NIH-NINDS, the Food and Drug Administration, the Familial Dysautonomia Foundation, and the HSAN IV Foundation. J.-A. Palma reports research funding from the NIH. R. Vickery is an employee of Theravance Biopharma Ireland Limited and is a shareholder. L. Norcliffe-Kaufmann and B. Zheng are employees of Theravance Biopharma US, LLC and are shareholders. D. Lewin is a contractor for Theravance Biopharma Ireland Limited. T. Guerin is an employee of Theravance Biopharma Ireland Limited and is a shareholder.
